Pivotal results from the Phase 3 Breakwater trial showed 51% risk reduction in death compared to standard-of-care treatment
The company also announced results for the third quarter, reporting sales at Rs. 992 crore, flat versus year ago
Usnoflast has previously also received ‘Orphan Drug Designation (ODD)’ from the USFDA
Facility also named 2025 ISPE Facility of the Year Winner for Social Impact - Unmet Medical Needs
Adjusted Profit After Tax (PAT) for the year ended March 31, 2025 was at Rs. 1,389.4 crore
Record international participation reflects renewed momentum in pharma manufacturing and global sourcing, as easing tariffs fuel growth
Q4 FY25 PAT stood at Rs. 90.7 crore as compared to Rs.77.6 crore in Q4 FY24
EBITDA for the period rose by 23.2% to Rs. 3,797 million
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
She has held senior positions at Coca-Cola in China and PepsiCo in India
Subscribe To Our Newsletter & Stay Updated
